Earl M. (Duke) Collier, Jr. is Executive Chairman of Arsenal Medical and serves as CEO of 480 Biomedical. For many years, Mr. Collier was executive vice president at Genzyme Corporation. He has also served as president of Vitas Healthcare, a partner at the Washington, DC-based law firm of Hogan and Hartson (now Hogan Lovells) and as Deputy Administrator of the Health Care Finance Administration (now CMS) in the Department of Health and Human Services. Mr. Collier sits on the boards of 480 Biomedical, Arsenal Medical, Capricor, Transmedics and Newton-Wellesley Hospital. He earned a Bachelor of Arts at Yale University and received a law degree from the University of Virginia Law School.
James J. Barry, Ph.D.
President and Chief Executive Officer
James J. Barry, Ph.D., is President and CEO of Arsenal Medical. Prior to Arsenal Medical, Dr. Barry held a variety of senior positions at Boston Scientific, most recently Sr. Vice President of Corporate Technology Development where he oversaw Corporate R&D and preclinical science. While at Boston Scientific, Dr. Barry initiated and led the company’s drug eluting stent programs. Under Dr. Barry’s leadership, the TAXUS™ drug-eluting coronary stent was developed and became the most successful medical device ever launched, attaining annual sales exceeding $3 billion. Prior to joining Boston Scientific, Dr. Barry held positions at Howmedica and at Kontron Instruments. Dr. Barry is the author of multiple articles in peer reviewed publications and holds more than 35 U.S. patents. He currently serves on the advisory boards of Massachusetts Life Sciences Center, University of Massachusetts-Lowell College of Sciences, and Yale University’s College of Biomedical Engineering. Dr. Barry holds a Ph.D. in Biochemistry from the University of Massachusetts-Lowell and a B.A. in chemistry from Saint Anselm College.
Toby Freyman, Ph.D.
Vice President, Research and Development
Prior to joining Arsenal Medical, Dr. Freyman was an Associate Principal with Charles River Associates (CRA) where he was involved in the launch of new bio-pharmaceutical products. Before CRA, Dr. Freyman was a Principal Engineer with Boston Scientific Corporation’s Corporate Research and Advanced Technology Development group. In this capacity, he focused on the identification and development of combination products to treat cardiovascular diseases. While at Boston Scientific, Dr. Freyman managed a group of senior-level scientists and established partnerships with leading academic and corporate collaborators. Dr. Freyman has 12 scientific publications and presentations, 23 patents and 13 patent applications. He holds a Ph.D. in Materials Engineering from MIT, where he received a National Institutes of Health Graduate Fellowship through a joint program with Harvard and MIT.
Dr. Sharma leads product development for Arsenal Medical's novel foam-based technology platform for treatment of non-compressible hemorrhage, directing a core team through ideation and filing of intellectual property, proof of concept and pre-clinical testing, and clinical system design. Under Dr. Sharma's scientific leadership, the company gained significant funding from DARPA/ARO for development of this hemorrhage control system. Prior to Arsenal, Dr. Sharma served as a core team member at 480 Biomedical, advancing the company's innovative biodegradable vascular scaffold from concept to pre-clinical proof-of-concept. Dr. Sharma was responsible for materials selection and drug formulation efforts for the scaffold. Dr. Sharma earned a Ph.D. from Princeton University in Chemical Engineering and a B.S.E. with Honors from Purdue University. During a post-doctoral fellowship in Bioengineering at Rice University, Dr. Sharma was awarded a NIH Training Grant in Nanobiology. Dr. Sharma has authored 12 peer-reviewed scientific publications and is an inventor on 10 issued or pending patents.